Thermo Enables Greater Flexibility for ADMET Studies with Galileo LIMS v 3.2

Thermo Electron Corporation, the leading provider of analytical instruments and laboratory information management systems (LIMS), today announced enhancements to its Galileo LIMS™, providing greater flexibility for high throughput ADMET experiments that facilitate lead optimization in drug discovery.

Galileo is a LIMS designed specifically to support in vitro ADMET experiments, allowing users to design, calculate and report data from metabolic stability, drug-drug interaction, protein binding, permeability and enzyme kinetics studies. Version 3.2 now gives users greater control over the assays performed with user-definable study types and customizable calculations.

“Galileo 3.2 expands in vitro research capabilities by enabling the full range of ADMET assays via user-definable calculations,” said Dave Champagne, vice president and general manager of Thermo’s informatics business. “We continue to enhance Galileo with off-the-shelf functionality that users need to keep the study design flexible, while providing the benefits of a more standard approach to assay management, analysis, storage and reporting of the data.”

In addition to user-definable study types to increase flexibility, Galileo now offers user-configurable decision trees that allow the user to define scenarios under which flagged results require further review. Questionable data is quickly reviewed with a new ability to filter data sets and to flag data based on comments entered during analytical data review. Templating of design and output parameters, as well as result flagging, eliminates manual actions, saving time and reducing errors for users. For details on enhancements in Galileo 3.2, visit www.thermo.com/lims.

Galileo LIMS is offered as an alternative to manual calculations using spreadsheets, resulting in disparate files maintained in many locations in multiple file formats. The LIMS enables drug discovery researchers to conduct high throughput in vitro screening and profiling of compounds to determine at an earlier and less costly stage which compounds might develop into commercially viable therapeutic drugs. Galileo enhances the value of its acquired data by ensuring consistency of the ADME calculations and uploading to a corporate database for broad dissemination and use.